-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Ultragenyx Pharmaceutical at Buy, Announces Price Target of $80

Benzinga·07/28/2025 10:30:02
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy rating and announces Price Target of $80.